<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05049408</url>
  </required_header>
  <id_info>
    <org_study_id>STBM-CT-OSCC-DIA001</org_study_id>
    <nct_id>NCT05049408</nct_id>
  </id_info>
  <brief_title>Verification of Saliva MMP-1 as a Diagnostic Marker of Oral Cavity Cancer</brief_title>
  <official_title>Verification of Saliva MMP-1 as a Strong Diagnostic Marker of Oral Cavity Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>S&amp;T Biomed Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>S&amp;T Biomed Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to measure salivary matrix metalloproteinase-1 (MMP-1) using the&#xD;
      enzyme-linked immunosorbent assay (ELISA) we developed previously in patients with oral&#xD;
      potentially malignant disorders (OPMD), oral squamous cell carcinoma (OSCC), and healthy&#xD;
      participants. The purpose of this study is to evaluate the potential of the newly developed&#xD;
      salivary MMP-1 ELISA as an adjunctive tool to aid in diagnosis of OSCC.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 17, 2011</start_date>
  <completion_date type="Actual">December 7, 2016</completion_date>
  <primary_completion_date type="Actual">December 7, 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Sensitivity and Specificity (both range from 0 to 1, the higher the better) of salivary MMP-1 levels as a diagnostic marker for OSCC</measure>
    <time_frame>30 days from initial sample obtained for this study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>ROC analysis of non-cancer group versus OSCC patients to find the optimal cutoff as the maximum of Youden's index (calculated as sensitivity + specificity - 1 and ranges from 0 to 1, the higher the better)</measure>
    <time_frame>30 days from initial sample obtained for this study</time_frame>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Actual">1160</enrollment>
  <condition>Oral Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>Group OSCC</arm_group_label>
    <description>Patients with Oral Squamous Cell Carcinoma (OSCC)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group OPMD</arm_group_label>
    <description>Patients with oral potentially malignant disorders (OPMD)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group HC</arm_group_label>
    <description>Healthy Control</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>MMP-1 Enzyme Linked Immunosorbent assay (ELISA)</intervention_name>
    <description>The MMP-1 ELISA is to measure salivary MMP-1 levels of participants</description>
    <arm_group_label>Group HC</arm_group_label>
    <arm_group_label>Group OPMD</arm_group_label>
    <arm_group_label>Group OSCC</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Randomly selected samples whose donors meeting the eligibility criteria from tissue bank&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Group OSCC: patients with lesions of OSCC&#xD;
&#xD;
          -  Group OPMD: patients with lesions of OPMD&#xD;
&#xD;
          -  Group HC: healthy subjects who are not suffering from any oral lesions and having&#xD;
             behaviors of smoking, and/or betel nut chewing&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects having personal history of other cancers or severe diseases&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Kaohsiung Chang Gung Memorial Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chi-Mei Medical Center</name>
      <address>
        <city>Tainan</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <results_reference>
    <citation>Chang YT, Chu LJ, Liu YC, Chen CJ, Wu SF, Chen CH, Chang IY, Wang JS, Wu TY, Dash S, Chiang WF, Chiu SF, Gou SB, Chien CY, Chang KP, Yu JS. Verification of Saliva Matrix Metalloproteinase-1 as a Strong Diagnostic Marker of Oral Cavity Cancer. Cancers (Basel). 2020 Aug 13;12(8). pii: E2273. doi: 10.3390/cancers12082273.</citation>
    <PMID>32823758</PMID>
  </results_reference>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 10, 2021</study_first_submitted>
  <study_first_submitted_qc>September 10, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 20, 2021</study_first_posted>
  <last_update_submitted>September 22, 2021</last_update_submitted>
  <last_update_submitted_qc>September 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mouth Neoplasms</keyword>
  <keyword>Head and Neck Neoplasms</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mouth Neoplasms</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

